Pulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?

Pulmatrix, Inc. (NASDAQ:PULM) shares passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.15 and traded as low as $1.18. Pulmatrix shares last traded at $1.20, with a volume of 14,565 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Pulmatrix Trading Down 4.8%

The business’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $3.30. The company has a market capitalization of $4.38 million, a price-to-earnings ratio of -0.85 and a beta of 1.97.

Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pulmatrix stock. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix at the end of the most recent reporting period. 11.84% of the stock is owned by institutional investors and hedge funds.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).